September 27, 2017 10:34 AM EDT
News Briefing

Ma­teon punts failed late-stage can­cer drug, ax­es staffers; Medi­vir boost­ed by os­teoarthri­tis da­ta

Shehla Shakoor

Managing Director

⇨ The pen­ny stock biotech Ma­teon Ther­a­peu­tics $MATN, for­mer­ly Ox­i­Gene, says it is scrap­ping a Phase II/III ovar­i­an can­cer study of CA4P in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times